MA45375A - Composés hétérocycliques utilisés en tant qu'agents antibacteriens - Google Patents

Composés hétérocycliques utilisés en tant qu'agents antibacteriens

Info

Publication number
MA45375A
MA45375A MA045375A MA45375A MA45375A MA 45375 A MA45375 A MA 45375A MA 045375 A MA045375 A MA 045375A MA 45375 A MA45375 A MA 45375A MA 45375 A MA45375 A MA 45375A
Authority
MA
Morocco
Prior art keywords
compounds used
antibacterial agents
heterocyclic compounds
heterocyclic
antibacterial
Prior art date
Application number
MA045375A
Other languages
English (en)
Inventor
Jérôme Émile Georges Guillemont
Pierre Jean-Marie Bernard Raboisson
Abdellah Tahri
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA45375A publication Critical patent/MA45375A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
MA045375A 2016-06-16 2017-06-15 Composés hétérocycliques utilisés en tant qu'agents antibacteriens MA45375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174722 2016-06-16

Publications (1)

Publication Number Publication Date
MA45375A true MA45375A (fr) 2019-04-24

Family

ID=56132839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045375A MA45375A (fr) 2016-06-16 2017-06-15 Composés hétérocycliques utilisés en tant qu'agents antibacteriens

Country Status (12)

Country Link
US (1) US20200308169A1 (fr)
EP (1) EP3472152A1 (fr)
JP (1) JP2019518050A (fr)
KR (1) KR20190018681A (fr)
CN (1) CN109415349A (fr)
AU (1) AU2017286370B2 (fr)
BR (1) BR112018075939A2 (fr)
CA (1) CA3025727A1 (fr)
EA (1) EA201990044A1 (fr)
MA (1) MA45375A (fr)
MX (1) MX2018015657A (fr)
WO (1) WO2017216283A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
WO2017049321A1 (fr) 2015-09-17 2017-03-23 Miller Marvin J Composés hétérocycliques contenant de la benzylamine et compositions utiles contre une infection mycobactérienne
EP3472158A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques en tant qu'agents antibacteriens
EP3589323B1 (fr) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Polythérapie pour le traitement de la tuberculose
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
MX2022003037A (es) 2019-09-13 2022-04-07 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3151712A1 (fr) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Inhibiteurs de cytochrome bd comme agents antibacteriens pour le traitement de la tuberculose
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214519A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2022214520A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2024223859A1 (fr) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Composés antibactériens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343458T3 (es) 2002-07-25 2010-08-02 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores de micobacterias.
RU2608611C2 (ru) * 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
WO2014015167A2 (fr) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac Composés anti-infectieux 5,5-hétéroaromatiques
CN105745208A (zh) * 2013-08-02 2016-07-06 韩国巴斯德研究所 一种抗感染化合物
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用

Also Published As

Publication number Publication date
EP3472152A1 (fr) 2019-04-24
MX2018015657A (es) 2019-03-14
EA201990044A1 (ru) 2019-05-31
KR20190018681A (ko) 2019-02-25
AU2017286370A1 (en) 2018-12-06
BR112018075939A2 (pt) 2019-04-09
JP2019518050A (ja) 2019-06-27
CN109415349A (zh) 2019-03-01
CA3025727A1 (fr) 2017-12-21
AU2017286370B2 (en) 2021-09-09
US20200308169A1 (en) 2020-10-01
WO2017216283A1 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux